VEGF-Inhibitor in Mesothelioma Treatment
Cediranib combined with cisplatin-pemetrexed has a reasonable toxicity profile and preliminary promising efficacy.
Raleigh, NC (PRWEB)
June 18, 2017
A new clinical trial of the VEGF-inhibitor cediranib suggests that, at the right dose, the drug might safely be used to improve the effectiveness of standard chemotherapy for pleural mesothelioma. Surviving Mesothelioma has published a new article on the trial. Click here to read it now.
For the Phase I trial, doctors at several US cancer centers helped test a mesothelioma treatment combination including the oral cancer drug cediranib the the standard mesothelioma chemotherapy drugs pemetrexed…
Read the full article from the Source…